Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations

Clinical Immunology

Volumn 112, Issue 2, 2004, Pages 190-199

  Blank, Miri ^b   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Anti beta 2 glycoprotein I; Antiphospholipid syndrome; Infection

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; BACTERIAL ANTIGEN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CIPROFLOXACIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ANTIGEN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BACTERIAL INFECTION; BYSTANDER EFFECT; CLINICAL FEATURE; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MOLECULAR MIMICRY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SACCHAROMYCES CEREVISIAE; SEQUENCE HOMOLOGY; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 3042796984     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.02.018     Document Type: Article

References (100)

1. Harris E.N., Gaharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S., Hughes G.R.V. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2:1983;1211-1214
2. Hughes G.R.V., Harris E.N., Gharavi A.E. The anti-cardiolipin syndrome. J. Rheumatol. 13:1986;486-489
3. Asherson R.A., Cervera R., Piette J.C., Shoenfeld Y. Milestones in the antiphospholipid syndrome. Asherson R.A., Cervera R., Piette J.C., Shoenfeld Y. The Antiphospholipid Syndrome II - Autoimmune Thrombosis. 2002;3-9 Elsevier, Amsterdam
4. Galli M., Comfurious P., Massen C., Hemker M.H., Be-Bates P.J., van-Breda-Vriesman P.J. Anti-cardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547
5. Cervera R., Piette J.C., J. Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 46:2002;1019-1027
6. Asherson R.A., Cervera R. Unusual manifestations of the antiphospholipid syndrome. www.rheuma21st.com/cutting_index.html:2002
7. Willems G.M., Janssen M.P., Pelsers M.M., Comfurius P., Galli M., Zwaal R.F., Bevers E.M. Role of divalency in the high-affinity binding of anticardiolipin antibody 2-glycoprotein I complexes to lipid membranes. Biochemistry. 35:1996;13833-13842
8. Schwarzenbacher R., Zeth K., Diederichs K., Gries A., Kostner G.M., Laggner P., Prassl R. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 18:1999;6228-6239
9. Bouma B., de Groot P.G., Jean M.H., van den Elsen J.M.L., Ravelli R.B.G., Schouten A., Simmelink M.J.A., Derksen R.W.M., Kroon J., Gros P. Adhesion mechanism of human beta2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18:1999;5166-5174
10. Brighton T.A., Hogg P.J., Dai Y.P., Murray B.H., Chong B.H., Chesterman C.N. β2glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br. J. Haematol. 93:1996;185-194
11. Koike T., Ichikawa K., Atsumi T., Kasahara H., Matsuura E. Beta 2-glycoprotein I-anti-beta 2-glycoprotein I interaction. J. Autoimmun. 15:2000;97-100
12. Manfredi A.A., Rovere P., Heltai S., Galati G., Nebbia G., Tincani A., Lestrieri G., Sabbadini G. Apoptotic cell clearance in systematic lupus erythematosus II. Role of beta-2-glycoprotein I. Arthritis Rheum. 41:1998;215-223
13. Balasubramanian K., Schroit A.J. Characterization of phosphatidylserine dependent beta 2-glycoprotein I macrophage interactions. J. Biol. Chem. 273:1998;29272-29277
14. 2-glycoprotein I (apolipoprotein H). J. Clin. Invest. 90:1992;1105-1111
15. 2-glycoprotein I or anticardiolipin antibodies alone. Clin. Exp. Immunol. 93:1993;269-273
16. 2-glycoprotein-I) induces experimental APS in naive mice. J. Autoimmun. 7:1994;441-447
17. 2-glycoprotein I. J. Investig. Med. 44:1996;69
18. 2-glycoprotein I. Clin. Exp. Immunol. 101:1995;78-82
19. 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. J. Immunol. 161:1998;5303-5312
20. Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179:1994;457-462
21. Horkko S., Miller E., Branch D.W., Palinski W., Witztum J.L. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc. Natl. Acad. Sci. U. S. A. 94:1997;10356-10361
22. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 346:2002;752-763
23. Rauch J., Subang R., D'Agnillo P., Koh J.S., Levine J.S. Apoptosis and the antiphospholipid syndrome. J. Autoimmun. 15:2000;231-235
24. Sorice M., Circella A., Misasi R., Pittoni V., Garofalo T., Cirelli A., Pavan A., Pontieri G.M., Valesini G. Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin. Exp. Immunol. 122:2000;277-284
25. Cocca B.A., Seal S.N., D'Agnillo P., Mueller P.Y.M., Katsikis P.D., Rauch J., Weigert M., Radic M.Z. Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13826-13831
26. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., Tobar A., Shoenfeld Y. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest. 109:2002;797-804
27. Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X.W., Colden-Stanfield M., Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 46:2002;545-552
28. Blank M., Shoenfeld Y., Cabilli S., Heldman Y., Fridkin M., Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc. Natl. Acad. Sci. 96:1999;5164-5168
29. Gharavi A.E., Pierangeli S.S., Harris N.E. New developments in viral peptides and APL induction. J. Autoimmun. 15:2000;227-230
30. Subang R., Levine J.S., Janoff A.S., Davidson S.M., Taraschi T.F., Koike T., Minchey S.R., Whiteside M., Tannenbaum M., Rauch J. Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies. J. Autoimmun. 15:2000;21-32
31. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., Atsumi T., Sakairi N., Yasuda T., Voelker D.R., Koike T. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res. 42:2001;697-709
32. Liu Q., Kobayashi K., Furukawa J., Inagaki J., Sakairi N., Iwado A., Yasuda T., Koike T., Voelker D.R., Matsuura E. Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res. 43:2002;1486-1495
33. Shoenfeld Y. The EuroAPS Study Group Prevalence and clinical correlations of antibodies against six β2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J. Clin. Immunol. 22:2003;337-383
34. Shi W., Chong B.H., Chesterman C.N. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood. 81:1993;1255-1262
35. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J. Immunol. 153:1994;1328-1332
36. Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemostasis. 79:1998;276-281
37. Sthoeger Z.M., Mozes E., Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc. Natl. Acad. Sci. U. S. A. 90:1993;6464-6467
38. George J., Blank M., Levy Y., Meroni P.L., Damianovich M., Tincani A., Shoenfeld Y. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 97:1998;900-906
39. Gharavi A.E., Pierangeli S.S., Colden-Stanfield M., Liu X.W., Espinola R.G., Harris E.N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in-vivo and in-vitro. J. Immunol. 163:1999;2922-2927
40. Raschi E., Testoni C., Bosisio D., Borghi M.O., Koike T., Mantovani A., Meroni P.L. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 101:2003;3495-3500
41. Pierangeli S.S., Xiao W., Liu X.W., Anderson G., Barker J.H., Harris E.N. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation. 94:1996;1746-1751
42. Pierangeli S.S., Liu X.W., Espinola R., Olee T., Zhu M., Harris N.E., Chen P.P. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb. Haemostasis. 84:2000;388-395
43. Branch D.W., Dudley D.J., Mitchell M.D., Creighton K.A., Abott T.M., Hammond E., Daynes R.A. Immunoglobulin G fractions from patients with anti-phospholipid antibodies cause fetal death in BALBA/c mice: a model for autoimmune fetal loss. Am. J. Obstet. Gynecol. 163:1990;210-216
44. Blank M., Cohen M.J., Toder V., Shoenfeld Y. Induction of primary anti-phospholipid syndrome in mice by passive transfer of anti-cardiolipin antibodies. Proc. Natl. Acad. Sci. U. S. A. 88:1991;3069-3073
45. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., Espinola R., Xiaowei L.E., Mao D., Vialpando C.G., Salmon J.E. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195:2002;200-211
46. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies: a mouse model. J. Clin. Invest. 100:1997;613-619
47. Blank M., Waisman A., Mozes E., Koike T., Shoenfeld Y. Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome. Int. Immunol. 11:1999;1917-1926
48. Giles I.P., Haley J.D., Nagl S., Isenberg D.A., Latchman D.S., Rahman A. A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Semin. Arthritis Rheum. 32:2003;246-265
49. Arvieux J., Renaudineau Y., Mane I., Perraut R., Krilis S.A., Youinou P. Distinguishing features of anti-beta2-glycoprotein-I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb. Haemostasis. 87:2002;599-605
50. Wang M.X., Kandiah D.A., Ichikawa K., Khamashta M., Hughes G., Koike T., Roubey R., Krilis S.A. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J. Immunol. 155:1995;1629-1636
51. Gharavi A.E., Pierangeli S.S., Colden Stanfield M., Liu X.W., Espinola R.G., Harris E.N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J. Immunol. 163:1999;2922-2927
52. Arai T., Yoshida K., Kaburaki J., Inoko H., Ikeda Y., Kawakami Y., Kuwana M. Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood. 98:2001;1889-1896
53. Hong D.P., Hagihara Y., Kato H., Goto Y. Flexible loop of beta 2-glycoprotein I domain V specifically interacts with hydrophobic ligands. Biochemistry. 40:2001;8092-8100
54. Ito H., Matsushita S., Tokano Y., Nishimura H., Tanaka Y., Fujisao S., Mitsuya H., Hashimoto H., Nishimura Y. Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity. Hum. Immunol. 61:2000;366-377
55. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15542-15546
56. Iverson G.M., Reddel S., Victoria E.J., Cockerill K.A., Wang Y.X., Marti-Renom M.A., Sali A., Marquis D.M., Krilis S.A., Linnik M.D. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J. Immunol. 169:2002;7097-7103
57. Visvanathan S., Scott J.K., Hwang K.K., Banares M., Grossman J.M., Merrill J.T., FitzGerald J., Chukwuocha R.U., Tsao B.P., Hahn B.H., Chen P.P. Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 48:2003;737-745
58. Zandman-Goddard G., Blank M., Shoenfeld Y. Antiphospholipid antibodies and infections - Drugs. Asherson R.A., Cervera R., Shoenfeld Y., Piette J.-C. The Antiphospholipid Syndrome 11. Autoimmune Thrombosis. 2002;343-358 Elsevier
59. Uhtman I.W., Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin. Arthritis Rheum. 31:2002;256-263
60. Asherson R.A., Cervera R. Antiphospholipid antibodies and infections. Ann. Rheum. Dis. 62:2003;388-393
61. Cervera R., Asherson R.A., Acevedo M.L., et al. Antiphospholipid syndrome triggered by infections: a report of two cases and a review of clinical presentations in 100 patients. Semin. Arthritis Rheum. 2003;. (in press)
62. Blank M., Asherson R.A., Cervera R., Shoenfeld Y. Antiphospholipid syndrome infectious origin. J. Clin. Immunol. 24:2004;12-23
63. Cicconi V., Carloni E., Franceschi F., Nocente R., Silveri N.G., Manna R., Servidei S., Bentivoglio A.R., Gasbarrini A., Gasbarrini G. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am. J. Med. 111:2001;163-164
64. Eslick G.D., Yan P., Xia H.H., Murray H., Spurrett B., Talley N.J. Foetal intrauterine growth restrictions with Helicobacter pylori infection. Aliment. Pharmacol. Ther. 16:2002;1677-1682
65. Figura N., Piomboni P., Ponzetto A., Gambera L., Lenzi C., Vaira D., Peris C., Lotano M.R., Gennari L., Bianciardi L., Renieri L.T., Valensin P.E., Capitani S., Moretti E., Colapinto R., Baccetti B., Gennari C. Helicobacter pylori infection and infertility. Eur. J. Gastroenterol. Hepatol. 14:2002;663-669
66. Grau A.J., Buggle F., Lichy C., Brandt T., Becher H., Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J. Neurol. Sci. 186:2001;1-5
67. Pellicano R., Broutet N., Ponzetto A., Megraud F. Helicobacter pylori: from the stomach to the heart. Eur. J. Gastroenterol. Hepatol. 11:1999;1335-1337
68. Aguejouf O., Mayo K., Monteiro L., Doutremepuich F., Doutremepuich C., Megraud F. Increase of arterial thrombosis parameters in chronic Helicobacter pylori infection in mice. Thromb. Res. 108:2002;245-248
69. Pellicano R., Broutet N., Ponzetto A., Megraud F. Helicobacter pylori: from the stomach to the heart. Eur. J. Gastroenterol. Hepatol. 11:1999;1335-1337
70. Krisher K., Cunningham M.W. Myosin: a link between streptococci and heart. Science. 227:1985;413-415
71. Bronze M.S., Dale J.B. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J. Immunol. 151:1993;2820-2828
72. Benoist C., Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2:2001;797-801
73. Shafran I., Piromalli C., Decker J.W., Sandoval J., Naser S.A., El-Zaatari F.A. Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients. Dig. Dis. Sci. 47:2002;2079-2081
74. Aichbichler B.W., Petritsch W., Reicht G.A., Wenzl H.H., Eherer A.J., Hinterleitner T.A., Auer-Grumbach P., Krejs G.J. Anti-cardiolipin antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 44:1999;852-856
75. Thong B.Y., Chng H.H., Ang C.L., Ho M.S. Recurrent venous thromboses, anti-cardiolipin antibodies and Crohn's disease. QJM. 95:2002;253-255
76. Koutroubakis I.E., Petinaki E., Anagnostopoulou E., Kritikos H., Mouzas I.A., Kouroumalis E.A., Manousos O.N. Anti-cardiolipin and anti-beta2- glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43:1998;2507-2512
77. Krause I., Monselise Y., Milo G., Weinberger A. Anti-Saccharomyces cerevisiae antibodies-a novel serologic marker for Behcet's disease. Clin. Exp. Rheumatol. 20(Suppl 26):2002;S21-S24
78. Houman H., Lamloum M., Ben Ghorbel I., Khiari-Ben Salah I., Miled M. Vena cava thrombosis in Behcet's disease. Analysis of a series of 10 cases. Ann. Med. Interne (Paris). 150:1999;587-590
79. El-Ageb E.M., Al-Maini M.H., Al-Shukaily A.K., Al-Farsi Y., Richens E.R. Clinical features of Behcet's disease in patients in the sultanate of oman; the significance of antiphospholipid antibodies? Rheumatol. Int. 21:2002;176-181
80. Mukai Y., Tsutsui H., Todaka K., Mohri M., Hirai N., Arai H., Takeshita A. Total occlusion of inferior vena cava in a patient with antiphospholipid antibody syndrome associated with Behcet's disease. Jpn. Circ. J. 65:2001;837-838
81. Famularo G., Antonelli S., Barracchini A., Menichelli M., Nicotra G.C., Minisola G. Catastrophic antiphospholipid syndrome in a patient with Behcet's disease. Scand. J. Rheumatol. 31:2002;100-102
82. Oldstone M.B. Molecular mimicry and immune-mediated diseases. FASEB J. 12:1998;1255-1265
83. Karlsen A.E., Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity. Semin. Immunol. 10:1998;25-34
84. Albert L.J., Inman R.D. Molecular mimicry and autoimmunity. N. Engl. J. Med. 341:1999;2068-2074
85. Gharavi E.E., Chaimovich H., Cucurull E., Celli C.M., Tang H., Wilson W.A., Gharavi A.E. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus. 8:1999;449-455
86. Gharavi A.E., Pierangeli S.S., Harris E.N. Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced APL antibodies. Immunobiology. 207:2003;37-42
87. Medzhitov R., Janeway C. Jr. Innate immunity. N. Engl. J. Med. 343:2000;338-344
88. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:2001;675-680
89. Krieg A.M. A role for toll in autoimmunity. Nat. Immunol. 3:2002;423-424
90. Leadbetter E.A., Rifkin I.R., Marshak-Rothstein A. Toll-like receptors and activation of autoreactive B cells. Curr. Dir. Autoimmun. 6:2003;105-122
91. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416:2002;603-607
92. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745
93. Gallagher A., Perry J., Freeland J., Alexander F.E., Carman W.F., Shield L., Cartwright R., Jarrett R.F. Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated. Int. J. Cancer. 104:2003;624-630
94. Scarisbrick I.A., Rodriguez M. Hit-hit and hit-run: viruses in the playing field of multiple sclerosis. Curr. Neurol. Neurosci. Rep. 3:2003;265-271
95. Blank M., George J., Fishman P., Levy Y., Toder V., Savion S., Barak V., Koike T., Shoenfeld Y. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis Rheum. 41:1998;224-232
96. Dietrich G., Kaveri S.V., Kazatchkine M.D. Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin. Immunol. Immunopathol. 62:1992;S73-81
97. Bakimer R., Blank M., Kosashvilli D., Ichikawa K., Khamashta M.A., Hughes G.R., Koike T., Shoenfeld Y. Antiphospholipid syndrome and the idiotypic network. Lupus. 4:1995;204-208
98. Bakimer R., Guilburd B., Zurgil N., Shoenfeld Y. The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. Clin. Immunol. Immunopathol. 69:1993;97-102
99. Krause I., Wu R., Sherer Y., Patanik M., Peter J.B., Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus. Med. 12:2002;133-139
100. Shoenfeld Y. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J. Autoimmun. 9:1996;235-239